SCHEMBL1123499

SCHEMBL1123499

CC(CCCC(C)(C)N=C=O)CCN=C=O

nearest known ligand 0.30

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.30
CYP3A4 P08684 1/20 0.30
ALOX15 P16050 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28776035 0.87
SCHEMBL8339193 0.87
SCHEMBL3669733 0.81
SCHEMBL230924 0.80
SCHEMBL28403399 0.80 LMNA (0.40)
SCHEMBL1123598 0.78
SCHEMBL3266895 0.78
SCHEMBL868602 0.78 LMNA (0.33)
SCHEMBL231391 0.78
SCHEMBL28957825 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
EP-1985672-B1 Phase Change Ink Compositions XEROX CORP (US) 2011-02-09 EP claimed
US-7811370-B2 Phase change ink compositions XEROX CORPORATION (US) 2010-10-12 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
US-20080264288-A1 Phase change ink compositions XEROX CORPORATION. 2008-10-30 US claimed
US-20070189991-A1 Cosmetic compositon comprising a (Thio)urethane/ (thio)urea copolymer capable of forming at least 3 hydrogen bonds, and a method of cosmetic treatment L'OREAL S.A. (FR) 2007-08-16 US claimed
US-7256249-B2 Compositions for golf equipment ACUSHNET COMPANY (US) 2007-08-14 US claimed
EP-1797868-A1 Cosmetic composition comprising a (thio)urethane/(thio)urea copolymer capable of forming at least 3 hydrogen bonds, and process for cosmetic treatment L'Oréal (FR) 2007-06-20 EP claimed
US-20050272899-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2005-12-08 US claimed
EP-0241690-A2 Aliphatic diisocyanates and their use for the preparation of polyurethane polymers BAYER AG (DE) 1987-10-21 EP claimed
EP-2267062-B1 SUPRAMOLECULAR POLYMERS CONTAINING QUADRUPLE HYDROGEN BONDING UNITS IN THE POLYMER BACKBONE SUPRAPOLIX BV (NL) 2017-10-25 EP disclosed
US-9790394-B2 Floor coating compositions containing supramolecular polymers ROHM AND HAAS COMPANY (US) 2017-10-17 US disclosed
EP-1773903-B1 SUPRAMOLECULAR IONOMERS SUPRAPOLIX BV (NL) 2017-08-09 EP disclosed
EP-3016996-B1 FLOOR COATING COMPOSITIONS CONTAINING SUPRAMOLECULAR POLYMERS ROHM & HAAS (US) 2017-06-14 EP disclosed
US-9561165-B2 Cosmetic treatment processes and kit L'OREAL (FR) 2017-02-07 US disclosed
US-5334637-A Isocyanatocarboxylic acids, a process for their preparation and their use in coating compositions as cross-linking agents BAYER AKTIENGESELLSCHAFT (DE) 1994-08-02 US disclosed
EP-0600310-A1 Polyisocyanate mixtures, method for their preparation and their use BAYER AG (DE) 1994-06-08 EP disclosed
EP-0548669-A2 Isocyanato carboxylic acids, a method for their preparation and their use BAYER AG (DE) 1993-06-30 EP disclosed
US-4777220-A Process for the production of prepolymers containing isocyanate groups, prepolymers produced by this process and their use BAYER AKTIENGESELLSCHAFT (DE) 1988-10-11 US disclosed
EP-0241690-A2 Aliphatic diisocyanates and their use for the preparation of polyurethane polymers BAYER AG (DE) 1987-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070189991-A1 Cosmetic compositon comprising a (Thio)urethane/ (thio)urea copolymer capable of forming at least 3 hydrogen bonds, and a method of cosmetic treatment KRT18, TST, CTH MEN1 689/4885CYP3A4 2749/4885ALOX15 3184/4885
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 MEN1 2029/4885CYP3A4 4568/4885ALOX15 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.